Singapore has developed a groundbreaking device for diabetic patients capable of measuring their three-month average blood sugar levels in just six minutes. This innovation, a collaboration between NHG Polyclinics and local medical equipment firm SG Diagnostics, represents a significant leap from traditional methods that could take days to yield results. The device, known as the Rapid HbA1c Point-Of-Care-Test for Improved Care, provides patients with a long-term view of their glucose levels, which is crucial for managing the condition and predicting the risk of complications affecting organs like the eyes, kidneys, and heart.

The device is user-friendly: a finger prick using a lancet, blood collection with a small sampler similar to a floss pick, and then placing the blood onto a test strip and feeding it into an analyser. Two buffer solutions are added to maintain the blood's acidity. This process eliminates the need for venous blood extraction and laboratory processing, saving time and effort, especially for smaller clinics that may lack the necessary equipment. This innovation has already garnered an Exemplary Innovation Award at the 2025 Public Sector Transformation Awards.

Sold under the name PreciS-A HbA1c Analysis System, the test is self-administered and available on e-commerce platforms like Shopee and Lazada for S$466. A successful trial involving 30 patients using the system at home for six months has been conducted to test its applicability for home use. The device can also be used during home visits or community screenings, aligning with Singapore's Healthier SG preventive health initiative. With approximately 1 in 12 Singaporeans having diabetes in 2022, according to the National Population Health Survey, this device offers a vital tool for improving diabetes management and patient well-being.

Key Indicators

Signal for Market/Industry: This device signifies a shift in diabetes diagnostics and monitoring, reducing reliance on laboratories and accelerating treatment decision-making. This could lead to increased investment in point-of-care and home-use diagnostic devices.
Leading Indicators and Data: Around 300 GP clinics islandwide have already adopted the device. Reports indicate that about 1 in 12 Singaporeans had diabetes in 2022, suggesting a substantial market for these technologies.

Regional Perspective

This innovation highlights Singapore's research and development capabilities in medical technology. The device aligns with the Healthier SG initiative, reflecting the government's focus on preventive healthcare and patient self-management. Its availability through e-commerce platforms makes it accessible to a broader population, enhancing healthcare accessibility.

Analysis

The strategic importance of this device lies in its ability to empower patients and doctors with immediate access to critical data, allowing for quicker and more effective treatment adjustments. While the initial cost may be higher than traditional lab tests, the benefits of reduced doctor visits, improved disease management, and decreased long-term complication risks make it a valuable investment. Its success in Singapore could pave the way for its adoption in other markets, particularly in regions facing challenges with access to specialized laboratory services.